OHSU Foundation P.O. Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. This center will be for the community, and we hope people will reach out to be a part of it. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Having someone who understands the challenges is helpful.. 2001-2022 Oregon Health & Science University. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. All these new agents have shown promising anticancer activity in laboratory testing and are now being evaluated in patients. Where is Dr. Shivaani Kummar located? Dr. Kummar specializes in the care and treatment of patients with cancer. She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. OHSU is an equal opportunity affirmative action institution. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Select a country/territory to view shared publications and projects. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone Sort by citations Sort by year Sort by title. The couple says their ultimate goal is to develop new effective therapies for cancer. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. BAL0891 . And to train and inspire the next generation of doctors and scientists. Shivaani Kummar. . Sort. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. Notice of Privacy Practices Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. BYLINE. Dr. Kummar completed a residency at Emory University. Professor of Medicine, OHSU. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . By using this website, we will assume that you agree to the terms and conditions of our privacy policy. . Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Very few institutions do it well, but OHSU truly gets it, Kummar says. Will you join us. They have a high school-aged daughter and middle school-aged son. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Today is a global celebration of giving an opportunity to support the causes that matter the most to you. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. (OHSU/Kristyna Wentz-Graff). OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. (h.c.), Ph.D., FAACR. Shivaani Kummar. 1. cleveland, tx funeral homes share dancing on ice app for ipad tweet exhaustive list of cushing's syndrome symptoms share. OHSU is an equal opportunity affirmative action institution. 12 Reviews). Dr. If you made any changes in Pure these will be visible here soon. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. February 17, 2023. (h.c.), Ph.D., FAACR. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. She also leads the division of hematology & medical oncology in the OHSU School of Medicine. What is the importance of philanthropy to your work? Administrative Coordinator, Margaret Rogers Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Their partnership will be a perfect pairing.. Cited by. Year; Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. what was bolivar's ultimate goal? Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP Expanding scientific knowledge is a key mission of OHSU, Oregons only academic health center. middlesex county community college nursing program nj Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. 2022 ASCO Annual Meeting - Poster Session . Title. OHSU is an equal opportunity affirmative action institution. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. Spray Foam Equipment and Chemicals. Clinical trials Drug development oncology. She accepts multiple insurance plans. PHYSICIAN HELPLINE Phone: 1-866-742-4811 Fax: 650-320-9443 Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. Post author By ; aleko lm137 manual Post date July 1, 2022; police clearance certificate in saudi arabia . Together their goal is to find a cure for cancer. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. Dr. Dr. Kummar loves to spend time with her family, read, and go for long walks. Hung, M.D. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. The Knight Cancer Institutes Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. Recent external collaboration on country/territory level. I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. Their mission is clear: To give patients excellent care. She received her medical degree from Lady Hardinge Medical College and has been in practice for . A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. NPI Lookup NPI Database. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Dive into the research topics where Shivaani Kummar is active. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. Keep me signed in. Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD You may also qualify for Phase 1 Program trials. Clinical trials are research studies that test how well new medicines or treatments work in people. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Palliative Care Administrative Assistant. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research.

Oak House Manchester Student Room, Iola Funeral Home Obituaries, Articles S